Distinct representation of muscle weakness in QMG and MG-ADL

Furthermore, ocular and generalised weakness appear to respond differently to different types of therapy; prednisone confers the greatest benefit for ocular symptoms, and intravenous immunoglobulin or plasma exchange confer the greatest benefit for generalised symptoms.4 We suspect that discrepancie...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2018-03, Vol.17 (3), p.204-205
Main Authors: de Meel, Robert Henri Pasquale, Verschuuren, Jan J G M, Tannemaat, Martijn R
Format: Article
Language:English
Subjects:
Activities of Daily Living
Antibodies, Monoclonal, Humanized
Double-Blind Method
Humans
Muscle Weakness
Myasthenia Gravis
Receptors, Cholinergic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Furthermore, ocular and generalised weakness appear to respond differently to different types of therapy; prednisone confers the greatest benefit for ocular symptoms, and intravenous immunoglobulin or plasma exchange confer the greatest benefit for generalised symptoms.4 We suspect that discrepancies between QMG and MG-ADL in the current trial could be explained by a differential response of various muscle groups to eculizumab and the different quantitative representation of oculobulbar and generalised weakness by QMG and MG-ADL. JJGMV reports involvement in a National Institutes of Health-sponsored thymectomy trial (ClinicalTrials.gov, number NCT00294658); reports a FP7 European MG grant (602420); and is a consultant for Alexion Pharmaceuticals and arGEN-X. RHPdM declares no competing interests. 1 JF Howard Jr, K Utsugisawa, M Benatar, Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study, Lancet Neurol, Vol. 16, 2017, 976-986 2 JF Howard Jr, M Freimer, JJ Wang, SR Collins, JT Kissel, QMG and MG-ADL correlations: study of eculizumab treatment of myasthenia gravis, Muscle Nerve, Vol. 56, 2017, 328-330 3 GI Wolfe, RJ Barohn, DB Sanders, MP McDermott, Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis, Muscle Nerve, Vol. 38, 2008, 1429-1433 4 C Barnett, V Bril, M Kapral, AV Kulkarni, AM Davis, Myasthenia Gravis Impairment Index: responsiveness, meaningful change, and relative efficiency, Neurology, Vol. 89, 2017, 2357-2364
ISSN:1474-4422
1474-4465
DOI:10.1016/S1474-4422(18)30037-1